Review
Pharmacology & Pharmacy
Jurij Hanzel, Christopher Ma, Niels Vande Casteele, Reena Khanna, Vipul Jairath, Brian G. Feagan
Summary: In Crohn's disease and ulcerative colitis patients, extraintestinal manifestations can affect up to 50% of patients, mainly involving the musculoskeletal system and skin, with less common involvement of the hepatobiliary tract and eye. The pathophysiology of EIMs is poorly understood but may involve abnormal immune responses and cross-reactivity with self-antigens. Tumor necrosis factor antagonists have shown efficacy in treating EIMs, while vedolizumab's efficacy in treating EIMs remains uncertain.
Article
Medicine, General & Internal
Istvan Fedor, Eva Zold, Zsolt Barta
Summary: In patients with inflammatory bowel diseases (IBD), some individuals may experience extraintestinal manifestations (EIMs) before the diagnosis of IBD, with ulcerative colitis (UC) patients typically showing EIMs earlier than Crohn's disease (CD) patients. Furthermore, UC patients with pancolitis tend to develop EIMs earlier in the disease course and display EIMs more frequently before the diagnosis of IBD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Immunology
Yuanzhuo Wang, Ziqi Wan, Rui Jin, Tianming Xu, Yan Ouyang, Baihui Wang, Gechong Ruan, Xiaoyin Bai
Summary: Extraintestinal manifestations (EIMs) are common in patients with inflammatory bowel disease (IBD) and managing these manifestations is difficult. Recent research has found that tofacitinib (TOF) may be a promising option for treating EIMs. TOF may benefit EIMs in ulcerative colitis, and higher doses and longer treatment times may increase its effectiveness. However, more specific research and large prospective studies are needed.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Gerhard Rogler, Abha Singh, Arthur Kavanaugh, David T. Rubin
Summary: Inflammatory bowel diseases (IBDs) are systemic diseases that can affect not only the gut but also other organs, impacting the quality of life for patients. Understanding the prevalence, pathophysiology, and clinical presentation of extraintestinal manifestations (EIMs) is crucial for effective IBD treatment. EIMs commonly affect joints, skin, or eyes, but may also involve other organs.
Article
Gastroenterology & Hepatology
Alicia Algaba, Ivan Guerra, Elena Ricart, Eva Iglesias, Miriam Manosa, Javier P. Gisbert, Jordi Guardiola, Miguel Minguez, Beatriz Castro, Ruth de Francisco, Pilar Nos, Federico Bertoletti, Francisco Mesonero, Jesus Barrio, Maria Dolores Martin-Arranz, Xavier Calvet, Santiago Garcia-Lopez, Beatriz Sicilia, Gillermo Alcain, Maria Esteve, Lucia Marquez, Marta Piqueras, Laura Jimenez, Jose L. Perez-Calle, Luis Bujanda, Mariana Garcia-Sepulcre, Alejandra Fernandez, Irene Moraleja, Rufo Humberto Lorente, Orlando Garcia-Bosch, Ana Lamban, Isabel Blazquez, Esther Rodriguez, Jose M. Huguet, Alfredo J. Lucendo, Pedro Almela, David Busquets, Patricia Ramirez de la Piscina, Marcela Perez, Eugeni Domenech, Fernando Bermejo
Summary: This study analyzed the prevalence, characteristics, and potential risk factors associated with EIMs in patients with IBD. The results showed that around one-fifth of IBD patients may have associated EIMs, with rheumatic manifestations being the most common. Female patients with severe Crohn's disease were identified as the group with the highest risk of developing EIMs.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Matthew D. Coates, Shannon Dalessio, Vonn Walter, August Stuart, Nana Bernasko, Andrew Tinsley, Sanam Razeghi, Emmanuelle D. Williams, Kofi Clarke, Kent Vrana
Summary: An analysis of 383 IBD patients found that active cannabis users were more likely to report various symptoms, such as abdominal pain, gas, tenesmus, and arthralgias. However, these patients did not show increased frequency of active disease or IBD-associated complications compared to nonusers.
CANNABIS AND CANNABINOID RESEARCH
(2022)
Article
Medicine, General & Internal
Min-Kyung Yeo, Jae Ho Park, Sun Hyung Kang, Hee Seok Moon, Jae Kyu Sung, Hyun Yong Jeong, Ju Seok Kim
Summary: This study aimed to identify risk factors for extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) by analyzing patient characteristics. The prevalence of EIMs in IBD patients was 12.4%, with higher rates in those with Crohn disease (CD) compared to ulcerative colitis (UC). The most common types of EIMs were articular, cutaneous, ocular, and hepatobiliary. Longer follow-up periods (>10 years) and treatment with biologics were identified as risk factors for the occurrence of EIMs.
Article
Gastroenterology & Hepatology
Madeline Alizadeh, Kiran Motwani, Bernadette C. Siaton, Ameer Abutaleb, Jacques Ravel, Raymond K. Cross
Summary: This study provides the first comprehensive large-cohort assessment of the relationship between extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD). The study finds that female patients with Crohn's disease and ocular or dermatologic manifestations are most likely to develop multiple EIMs. Additionally, involvement of the right colon is predictive of inflammatory bowel disease-associated arthritis.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Moran Livne-Margolin, Daniel Ling, Shani Attia-Konyo, Chaya Mushka Abitbol, Ola Haj-Natour, Bella Ungar, Shomron Ben-Horin, Uri Kopylov
Summary: This study compared the effectiveness of vedolizumab and ustekinumab in treating extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) patients, and found no significant difference between the two in terms of EIM treatment.
DIGESTIVE AND LIVER DISEASE
(2023)
Review
Gastroenterology & Hepatology
Yakup Kilic, Shahed Kamal, Farah Jaffar, Danujan Sriranganathan, Mohammed Nabil Quraishi, Jonathan P. Segal
Summary: Inflammatory bowel disease (IBD) is a multisystem disease that affects various body systems. The extraintestinal manifestations of IBD are frequent and impact the morbidity and mortality of patients with UC and CD.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Gastroenterology & Hepatology
Lucas Guillo, Maria Abreu, Remo Panaccione, William J. Sandborn, Valderilio F. Azevedo, Lianne Gensler, Bahar Moghaddam, Vineet Ahuja, Sabrina A. Ali, Matthieu Allez, Ashwin N. Ananthakrishnan, Abhik Bhattacharya, Marla Dubinsky, Anne Griffiths, Ailsa Hart, Burton Korelitz, Paulo G. Kotze, Iommaso E. Koutroubakis, Peter L. Lakatos, James O. Lindsay, Fernando Magro, Gerassimos J. Mantzaris, Slew C. Ng, Cohn O'Morain, Julian Panes, Tom Maso Parigi, Zhihua Ran, Gerhard Rogler, David T. Rubin, David B. Sachar, Britta Siegmund, Flavio Steinwurz, Curt Tysk, Stephan Vavricka, Sofa G. Verstraete, Antoine P. Brezin, Anna K. Haemel, Axel Dignass, Bruce E. Sands, Silvio Danese, Laurent Peyrin-Biroulet
Summary: Extraintestinal manifestations are common in patients with inflammatory bowel disease and pose challenges for diagnosis and treatment. The EXTRA initiative aims to achieve international consensus on assessing these manifestations in clinical trials. A panel of experts identified methods for diagnosing extraintestinal manifestations and measuring treatment outcomes. They recommend specialist expertise for confirming the diagnosis in most cases, except for axial spondyloarthritis where typical symptoms and MRI can be sufficient. Easy-to-measure endpoints were identified for assessing treatment response without specialist involvement. Guidelines were proposed for comprehensive evaluation of extraintestinal manifestations in future trials.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Review
Genetics & Heredity
Ugo Cucinotta, Claudio Romano, Valeria Dipasquale
Summary: Inflammatory bowel diseases are chronic inflammatory conditions of the gastrointestinal tract, including Crohn's disease, ulcerative colitis, and IBD-U. Apart from affecting the intestines, they may also involve other organs and systems, causing a variety of extraintestinal manifestations.
Article
Integrative & Complementary Medicine
E. Wilke, W. Reindl, P. A. Thomann, M. P. Ebert, T. Wuestenberg, A. K. Thomann
Summary: The quality of life of individuals with inflammatory bowel diseases can be compromised by symptoms such as depression and fatigue which may not directly related to the intestinal inflammation. Yoga, with its combination of postures, breathing exercises and meditation, has been shown to have a positive impact on these symptoms. While current literature supports the feasibility and safety of yoga interventions as complementary treatment for patients with IBD, more research is needed to fully understand the effects of yoga on depression and fatigue in this population.
COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE
(2021)
Article
Gastroenterology & Hepatology
Guilherme Piovezani Ramos, Christina Dimopoulos, Nicholas M. McDonald, Laurens P. Janssens, Kenneth W. Hung, Deborah Proctor, Elizabeth Ruggiero, Sunanda Kane, David H. Bruining, William A. Faubion, Laura E. Raffals, Edward Loftus, Badr Al-Bawardy
Summary: The study found that approximately one-third of IBD patients experienced worsening EIMs after VDZ treatment, with peripheral arthritis being the most common type. Worsening of EIMs led to discontinuation of VDZ treatment, but there were no significant differences between the worsening and stable EIMs groups.
INFLAMMATORY BOWEL DISEASES
(2021)
Review
Oncology
Alessandro Massano, Luisa Bertin, Fabiana Zingone, Andrea Buda, Pierfrancesco Visaggi, Lorenzo Bertani, Nicola de Bortoli, Matteo Fassan, Marco Scarpa, Cesare Ruffolo, Imerio Angriman, Cristina Bezzio, Valentina Casini, Davide Giuseppe Ribaldone, Edoardo Vincenzo Savarino, Brigida Barberio
Summary: This review summarizes the evidence on the association between inflammatory bowel disease (IBD) and extraintestinal cancers (EICs), as well as the safety and management of immunomodulators and biologics for IBD patients with prior or current EICs.